Synapse - Ferrata Storti Foundation

Results (354)

Ag-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies

Meeting Abstract

DiNardo, C.; Stein, E. M.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Fathi, A. T.; Flinn, I.; Frankel, A.; Levine, R. L.; Medeiros, B. C.; more...
Haematologica (2015)

Fulltext@MSK | Save

Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies

Meeting Abstract

de Botton, S.; Pollyea, D. A.; Stein, E. M.; DiNardo, C.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I.; Altman, J. K.; more...
Haematologica (2015)

Fulltext@MSK | Save

DNMT3A R882 mutation promote chemoresistance and therapeutic relapse through impaired DNA-damage sensing

Meeting Abstract

Guryanova, O.; Shank, K.; Garrett-Bakelman, F.; Spitzer, B.; Ganzel, C.; Rapaport, F.; Keller, M.; Evangelista, L.; Glass, J.; Rowe, J.; more...
Haematologica (2015)

Fulltext@MSK | Save

BCl6 and EZH2 cooperate to assemble non-canonical PRC1-BCOR complex to mediate germinal center formation and promote lymphomagenesis by repressing bivalent chromatin domains

Meeting Abstract

Béguelin, W.; Teater, M.; Hatzi, K.; Jiang, Y.; Gascoyne, R. D.; Abdel-Wahab, O.; Shaknovich, R.; Bardwell, V. J.; Elemento, O.; Melnick, A. M.
Haematologica (2015)

Fulltext@MSK | Save

Outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with myelofibrosis (MF) exposed to JAK1/2 inhibitors

Meeting Abstract

Shanavas, M.; Popat, U.; Michaelis, L. C.; Fauble, V.; McLornan, D.; Klisovic, R.; Mascarenhas, J.; Tamari, R.; Arcasoy, M.; Davies, J.; more...
Haematologica (2015)

Fulltext@MSK | Save

A phase 1 trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory or relapsed lymphoma and multiple myeloma